Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children
- 1 February 2012
- journal article
- review article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 59 (2) , 161-169
Abstract
Antiretroviral therapy in children has expanded dramatically in low-income and middle-income countries. The World Health Organization revised its pediatric HIV guidelines to recommend initiation of antiretroviral therapy in all HIV-infected children younger than 2 years, regardless of CD4 count or clinical stage. The number of children starting life-long antiretroviral therapy should therefore expand dramatically over time. The early initiation of antiretroviral therapy has indisputable benefits for children, but there is a paucity of definitive information on the potential adverse effects. In this review, a comprehensive literature search was conducted to provide an overview of our knowledge about the complications of treating pediatric HIV. Antiretroviral therapy in children, as in adults, is associated with enhanced survival, reduction in opportunistic infections, improved growth and neurocognitive function, and better quality of life. Despite antiretroviral therapy, HIV-infected children may continue to lag behind their uninfected peers in growth and development. In addition, epidemic concurrent conditions, such as tuberculosis, malaria, and malnutrition, can combine with HIV to yield more rapid disease progression and poor treatment outcomes. Additional studies are required to evaluate the long-term effects of antiretroviral therapy in HIV-infected infants, children, and adolescents, particularly in resource-limited countries where concomitant infections and conditions may enhance the risk of adverse effects. There is an urgent need to evaluate drug–drug interactions in children to determine optimal treatment regimens for both HIV and coinfections.Keywords
This publication has 84 references indexed in Scilit:
- In Vitro Activity of Antiretroviral Drugs against Plasmodium falciparumAntimicrobial Agents and Chemotherapy, 2011
- Antiretroviral therapy and bone mineral measurements in HIV-infected youthsBone, 2010
- Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for TuberculosisAntiviral Therapy, 2010
- Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045AIDS, 2010
- HIV Infection, Malnutrition, and Invasive Bacterial Infection among Children with Severe MalariaClinical Infectious Diseases, 2009
- Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan childrenAIDS, 2007
- Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory SyndromeThe Journal of Infectious Diseases, 2007
- Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the Introduction of Protease Inhibitor–Based Highly Active Antiretroviral TherapyPediatrics, 2007
- How Can We Improve the Care of Severely Malnourished Children in Africa?PLOS Medicine, 2007
- Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2005